Overall, our data uncovered a previously unrecognized oncogenic mechanism of how SPHK1‐packaged EVs upregulate S1P in the ovarian cancer microenvironment, enhancing immune suppression through T cell exhaustion. Here, SPHK1 is linked to ovarian cancer.